Cargando…
Targeting Toxic RNAs that Cause Myotonic Dystrophy Type 1 (DM1) with a Bisamidinium Inhibitor
[Image: see text] A working hypothesis for the pathogenesis of myotonic dystrophy type 1 (DM1) involves the aberrant sequestration of an alternative splicing regulator, MBNL1, by expanded CUG repeats, r(CUG)(exp). It has been suggested that a reversal of the myotonia and potentially other symptoms o...
Autores principales: | Wong, Chun-Ho, Nguyen, Lien, Peh, Jessie, Luu, Long M., Sanchez, Jeannette S., Richardson, Stacie L., Tuccinardi, Tiziano, Tsoi, Ho, Chan, Wood Yee, Chan, H. Y. Edwin, Baranger, Anne M., Hergenrother, Paul J., Zimmerman, Steven C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2014
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015652/ https://www.ncbi.nlm.nih.gov/pubmed/24702247 http://dx.doi.org/10.1021/ja5012146 |
Ejemplares similares
-
Selective inhibition of MBNL1–CCUG interaction by small molecules toward potential therapeutic agents for myotonic dystrophy type 2 (DM2)(†)
por: Wong, Chun-Ho, et al.
Publicado: (2011) -
Delay of EGF-Stimulated EGFR Degradation in Myotonic Dystrophy Type 1 (DM1)
por: Alegre-Cortés, Eva, et al.
Publicado: (2022) -
Basilar Artery Dissection in Myotonic Dystrophy Type 1
por: Lee, Chan-Hyuk, et al.
Publicado: (2022) -
Cognitive deficits and CTG repeat expansion size in classical myotonic dystrophy type 1 (DM1)
por: Winblad, Stefan, et al.
Publicado: (2006) -
Blood Transcriptome Profiling Links Immunity to Disease Severity in Myotonic Dystrophy Type 1 (DM1)
por: Nieuwenhuis, Sylvia, et al.
Publicado: (2022)